恆瑞醫藥(600276.SH):擬以2000萬美元投資瓔黎藥業並獲得YY-20394聯合開發及商業化權益
格隆匯 2 月 8日丨恆瑞醫藥(600276.SH)公佈,公司擬以自籌資金2000萬美元認購Yingli Pharma Limited (瓔黎藥業有限公司,“瓔黎藥業”)6.67%的股份。根據相關法律、法規及《公司章程》有關規定,此次交易不構成關聯交易或重大資產重組,亦無需提交公司董事會及股東大會審議。
獲得YY-20394聯合開發和商業化權益:公司與瓔黎藥業的子公司上海瓔黎藥業有限公司(“上海瓔黎”)達成協議,上海瓔黎授予恆瑞醫藥針對PI3kδ抑制劑Linperlisib (研發代碼YY-20394,“YY-20394”)在大中華地區的聯合開發權益以及排他性獨家商業化權益。
瓔黎藥業是一家專業從事醫藥產品的研發、生產和銷售的企業,產品管線中包含各種小分子新藥。瓔黎藥業專注於血液瘤、實體瘤及腎相關代謝疾病相關藥品的研發及商業化。
YY-20394是瓔黎藥業研發的1類創新藥,是PI3Kδ (磷脂酰肌醇-3-激酶δ亞型)高選擇性抑制劑。PI3Kδ抑制劑可直接作用於淋巴瘤細胞,抑制Akt磷酸化,誘導細胞凋亡。其亦可通過影響腫瘤免疫環境,降低Treg細胞功能,增強CD8+T細胞活性,從而殺死實體瘤細胞。2017年6月上海瓔黎藥業有限公司收到國家藥品監督管理局(“國家藥監局”)核准簽發的YY-20394《藥物臨牀試驗批件》;2019年3月上海瓔黎藥業有限公司收到國家藥監局核准籤發的YY-20394《藥品補充申請批件》增加了更適應臨牀及商業化生產的新制劑規格。YY-20394片擬用於多種惡性腫瘤的治療。
研發方面,截至2020年12月,瓔黎藥業對YY-20394共計投入研發費用約1億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.